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Abstract
Background: Melanoma is the most deadly form of skin cancer. Expression of oncogenic BRAF or NRAS, which are
frequently mutated in human melanomas, promote the formation of nevi but are not sufficient for tumorigenesis.
Even with germline mutated p53, these engineered melanomas present with variable onset and pathology,
implicating additional somatic mutations in a multi-hit tumorigenic process.
Results: To decipher the genetics of these melanomas, we sequence the protein coding exons of 53 primary
melanomas generated from several BRAF
V600E or NRAS
Q61K driven transgenic zebrafish lines. We find that engineered
zebrafish melanomas show an overall low mutation burden, which has a strong, inverse association with the
number of initiating germline drivers. Although tumors reveal distinct mutation spectrums, they show mostly C> T
transitions without UV light exposure, and enrichment of mutations in melanogenesis, p53 and MAPK signaling.
Importantly, a recurrent amplification occurring with pre-configured drivers BRAF
V600E and p53
-/- suggests a novel
path of BRAF cooperativity through the protein kinase A pathway.
Conclusion: This is the first analysis of a melanoma mutational landscape in the absence of UV light, where tumors
manifest with remarkably low mutation burden and high heterogeneity. Genotype specific amplification of protein
kinase A in cooperation with BRAF and p53 mutation suggests the involvement of melanogenesis in these tumors.
This work is important for defining the spectrum of events in BRAF or NRAS driven melanoma in the absence of UV
light, and for informed exploitation of models such as transgenic zebrafish to better understand mechanisms
leading to human melanoma formation.
Background
Melanoma is a form of skin cancer known for its thera-
peutic resistance, aggressiveness and late metastatic
manifestation [1]. Activating mutations in BRAF (V600E)
or NRAS (Q61K) are collectively found in approximately
60% of human melanomas and result in the constitutive
signaling of the mitogen-activated protein kinase (MAPK)
pathway [2,3]. Although studies have shown a clear
dependence of tumor growth on MAPK signaling, most
nevi with BRAF
V600E or NRAS
Q61K mutations remain be-
nign for decades [4]. In zebrafish, expression of human
BRAF
V600E (BRAF)o rNRAS
Q61k (NRAS) in melanocytes
results in the growth of pigmented, nevus-like lesions that
also rarely progress to melanoma. Invasive melanomas
develop in these transgenic zebrafish only in combination
with engineered loss of p53 function [5,6], and yet manifest
with variable onset and penetrance, strongly suggesting that
these drivers are not sufficient for malignant melanoma
formation and the requirement for additional unknown,
somatic events.
Recent analyses of the genomes and exomes of human
melanoma have resulted in the identification of new
* Correspondence: afutreal@mdanderson.org
1Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK
6Department of Genomic Medicine, The University of Texas MD Anderson
Cancer Center, Houston, TX 77054, USA
Full list of author information is available at the end of the article
© 2013 Yen et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Yen et al. Genome Biology 2013, 14:R113
http://genomebiology.com/2013/14/10/R113mutations that are likely to contribute to the disease
formation or survival [7-11]. One confounding aspect
of discriminating drivers in melanoma is the elevated
background mutation burden due to UV mutagenesis,
although new algorithms have been developed to refine
this analysis [10]. We sought to build upon these studies
through a focused analysis of a set of engineered melano-
mas, to determine the spectrum of mutations in the
absence of UV light and to interrogate the role of BRAF,
NRAS and p53 in melanoma in transgenic zebrafish. Spe-
cifically, we used targeted exon enrichment and Illumina
sequencing to generate exome and copy-number alteration
data for 53 samples consisting of 38 BRAF-driven and 15
NRAS-driven primary zebrafish melanomas and cell lines
with additional perturbations. A detailed examination
of the spectrum of somatic point mutations, insertions,
deletions and amplifications is presented. Our analysis
reveals striking genetic heterogeneity, genotype-specific
mutation patterns and a potential novel path to BRAF-
driven tumorigenesis, providing insights into the events
important for cooperation with BRAF and NRAS in the
context of low mutation burden.
Results and discussion
Study set and sequencing overview
We collected matched zebrafish melanoma and normal
tissue from 53 transgenic zebrafish harboring tissue-specific
oncogenic alleles of human BRAF and NRAS under
a melanocyte-specific (mitf) promoter [5,6] (Table 1,
Figure 1; Additional file 1: Table S1). Specifically, 38 fish
expressed oncogenic BRAF
V600E (BRAF) and 15 expressed
oncogenic NRAS
Q61K (NRAS). The majority of samples
(33 BRAF and 14 NRAS individuals) carried at least one
germline, mutant p53 allele (p53
M214K [12]). While p53
itself has not traditionally been considered to be a major
tumor suppressor in melanoma development, inactivation
of CDKN2A/p16 is associated with loss of p53 activity
[13]. Further, the high mutation load in p53 and its
pathway components in melanoma also underscores its
importance [10]. Four BRAF fish harbored a germline
temperature-sensitive hypomorphic allele of mitf (mitf
vc7)
[14,15]. Of BRAF individuals with aberrant p53,3 8h a d
additional mutant germline alleles in mitf
-/- (known
as nacre
-/-) [16], ptena
hu1864 +/- [17] or mitf
vc7 [14,15].
Transgenic individuals with BRAF;p53
-/-;mitf
-/- were
manipulated with a miniCoopR shuttle vector system [18],
consisting of somatic mosaic rescue of MITF expression
in melanocytes along with SETDB1 [18] and transcription
factors KROX20, FOXD3 or OCT6, the biology and onco-
genicity of which are being investigated independently.
To analyze coding regions of the zebrafish genome, we
performed targeted exome capture on tumor and normal
DNA followed by 75 base paired-end Illumina (HiSeq)
sequencing (European Nucleotide Archive accessions
ERP003701, ERP003702). The bait set covered all protein
coding genes, 3’ UTRs and 5’ UTRs of the Zv8 and later
Zv9 genome for a combined coverage of 60 Mb. A total of
2,309 Gb of sequencing was generated, averaging approxi-
mately 21.8 Gb per sample (Additional file 1: Table S2).
Because of the complexity and diversity of the zebrafish
genome [19], we addressed the sensitivity and precision of
applying the CaVEMan substitution calling algorithm
[20] to zebrafish through two analyses: variant calling
simulations and comparison to additional callers. In the
first instance, we measured the performance of CaVEMan
in simulated zebrafish tumor and normal genomes, which
showed that the algorithm detected somatic substitutions
with both high sensitivity and precision within these
conditions (Additional file 2: Figure S1, Supplementary
text in Additional file 3). We next employed CaVEMan for
substitution calling on the zebrafish melanoma study set.
Through manual inspection of each variant, we determined
that a large proportion of these substitutions were false
positives (57%; Additional file 2: Figure S2A), many due to
germline variants that had been missed by the algorithm or
calls made on suboptimal alignments (Additional file 2:
Figure S2B). The low precision led us to manually examine
all variants to ensure an accurate collection was used for
downstream analysis.
In the second part of the analyses, we ascertained the
sensitivity of our algorithm on the zebrafish melanoma
dataset by comparing the CaVEMan calls for one sample
(ZD8a) to those from SomaticSniper [21] and String
Graph Assembler (SGA) [22]. Our results showed that
Table 1 Study set overview
Genotype Samples
mitf:BRAF
V600E 1
mitf:BRAF
V600E;p53
+/- 2
mitf:BRAF
V600E;p53
+/-; ptena
hu1874 +/- 1
mitf:BRAF
V600E;mitf
vc7+/+; 4
mitf:BRAF
V600E;mitf
vc7+/+;p53
+/- 4
mitf:BRAF
V600E; p53
-/-;mitf
-/-;mitf:MITF 6
mitf:BRAF
V600E;p53
-/-;mitf
-/-;mitf:MITF;mitf:foxd3 4
mitf:BRAF
V600E;p53
-/-;mitf
-/-;mitf:MITF;mitf:krox20 12
mitf:BRAF
V600E;p53
-/-;mitf
-/-mitf:MITF;mitf:krox20/foxd3/OCT6* 1
mitf:BRAF
V600E;p53
-/-;mitf
-/-;mitf:MITF;mitf:SETDB1 1
mitf:BRAF
V600E;p53
-/-;mitf
-/-;mitf:MITF;mitf:EGFP 1
mitf:NRAS1
Q61K 2
mitf:NRAS1
Q61K;p53
-/- 5
mitf:NRAS1
Q61K;p53
+/- 4
mitf:NRAS1
Q61K;p53
+/-;rps29
+/- 5
Total 53
The asterisk indicates that the genes krox20, foxd3 and OCT6 were each
expressed on separate plasmids for this tumor.
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somatic variants to the CaVEMan algorithm (Additional
file 2: Figure S2C-E). In spite of this marginal increase, we
added a subset of non-overlapping Sniper variants to
the CaVEMan calls, which we experimentally validated
through targeted enrichment and Illumina sequencing
(Additional file 2: Figure S3). All calls from this analysis
were then subject to a second, manual review.
Overview of substitutions and indels in engineered
zebrafish melanomas
We confirmed a total of 403 point mutations and 13
insertions and deletions (indels), the latter of which were
identified using Pindel [23] and processed using a similar
method to the substitutions (Figure 2A). Of the substitu-
tions, 79 were synonymous, 168 resulted in amino acid
changes, 16 were nonsense and 25 occurred at splice sites
(Additional file 1: Table S3). Eighty-five substitutions were
found in the 3' UTR and 26 in the 5' UTR, and one start
codon was gained. The ratio of 2.3:1 non-synonymous to
synonymous events was similar to the averages previously
reported in human melanoma [9,10]. The median number
of coding mutations per sample was four, significantly
fewer than the median of 171 in sun-exposed human
melanomas and closer to the median of nine in mucosal
and uveal melanomas, also originating from sun-shielded
sites [9]. Over half of the total number of mutations in
the study set was present in only eight samples (15%),
six of which had two or fewer engineered ‘initiating
drivers’. The highest number of substitutions were found
in samples with one or two initiating drivers: ZD0038a
(BRAF), ZD24a (NRAS), ZD23a (NRAS;p53
+/-) and ZD30a
(NRAS;p53
-/-).
Consistent with the low substitution burden, there were
few recurrent mutations. Two substitutions were found in
ttna and ttnb, the two largest protein-coding genes in the
zebrafish genome. No recurrent substitutions were found
in known melanoma genes or genes in the Cancer Gene
Census [24]. Over 60% of genes mutated in this study
were found to be mutated at least once in human mel-
anoma [9-11,25-27], which was unsurprising given the
extensive mutation load in the human disease. Substitutions
with predicted coding changes in known census cancer
genes included a nonsense mutation in ikzf and missense
mutations in nup214 and pik3cd, while a homozygous
missense substitution in the anaphase promoting complex
gene, anapc1, was identified in a BRAF, p53
+/- tumor
(ZD8a).
UV-independent mutation spectra and mutational
processes
Intriguingly, recent studies have shown that over half of
the driver mutations in human melanomas do not bear
the UV radiation-associated signature [10]. To explore the
nature of the non-UV events, we examined the mutation
spectrum in the engineered zebrafish melanomas developed
under conditions without detectable UV light, as deter-
mined using a standard laboratory photometer (Inter-
national Light 1400). As with most human cancers, C>T
substitutions (24.4%) constituted the prominent mutation
class across all samples, including ZD8a and ZD24a
(Figure 2C,D), which had substantial mutation burdens.
Remarkably, ZD0038a, which had the highest substitution
load (n=47), consisted of mutations occurring exclusively
at cytosine or guanine residues (Figure 2E), a mutation
signature that has not yet been described in human
Figure 1 Examples of zebrafish melanomas. BRAF (left panel) and NRAS (right panel) driven zebrafish melanomas in a p53
-/- background, with
specimen example (top panel) and histology (bottom panel).
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from one resulted in a predicted missense (n =21) or a
nonsense change (n =3). To determine if this was the
result of positive selection, we calculated the dN/dS ratio
using a mutation-selection model. We found that the rates
of missense and nonsense mutations for this sample
were approximately 5.5 and 9.8 times higher than ex-
pected by neutral evolution, respectively, a result unlikely
in the absence of positive selection (PdM/dS=0.030 and
PdNS/dS=0.031).
Similar to findings in non-sun-exposed human melano-
mas [9], no significant bias of mutations was found in any
class on any particular strand (Figure 2B). By comparison,
a mutation strand-bias caused by transcription-coupled
repair has been demonstrated in UV light-induced mel-
anomas, lung and breast cancers, all of which display
the characteristic signatures of their respective UV, to-
bacco and DNA repair mutagens [9,28,29]. The absence of
this signature in our samples suggests that these repair
processes are not overt unless triggered by a selective,
mutagenic pressure.
ZD8a, a BRAF and p53 mutant, presented two micro-
clusters of mutations. Twelve substitutions (40% of the
total load) spanned exons within a 4,500 bp interval of the
hoxd9a and hoxd10a genes (Figure 2F), while a second
cluster of five mutations was found within a 5 kb interval
(Additional file 2: Figure S4). These microclusters were
reminiscent of ‘kataegis’, hypermutated regions resulting
from a single event [30]. A close examination of the reads
revealed that the substitutions occurred in cis, had similar
variant allele fractions and were mostly C>T transitions
(n=12/26; Figure 2F). In human, patterns of kataegis have
been proposed to be related to mutational processes of
the AID/APOBEC family of enzymes, which modulate
antibody diversification by deaminating cytidines to deox-
yuridine within immunoglobulin genes [30,31]. Although
APOBEC emerged only in primates, they are believed to
have derived from the functionally conserved AID enzymes
[32], which may provide the mechanistic origin of these
clusters in zebrafish.
Insertions and deletions
Indels were sparse, with a total of 13 confirmed indels
across the 53 samples (Additional file 1: Table S4). This
is lower than the sample average of two to four indels in
human melanoma [9]. Eight indels were single base pair
indels, and all 13 (<5 bp) were flanked by tandem repeat
sequences on either side, evidence of a lapse in post-repli-
cative mismatch repair found commonly in breast cancer
genomes [30]. Ten indels were out of frame and likely to
cause loss of gene function. Four indels (36%) were found
in a sample mutant only in BRAF (ZD0038a). Interest-
ingly, a single nucleotide deletion resulting in a frameshift
mutation was found in pik3ip1 (V170fs*), which in human
directly binds to the p110 catalytic subunit of PIK3 and
negatively modulates its activity [33]. Its occurrence in a
BRAF, mitf
-/-, p53
-/- mutant sample is consistent with a
role for phosphatidylinositide 3-kinase (PI3K) cooperation
with MAPK deregulation in human melanoma [34].
Overview of copynumber changes
In total, 991 amplification segments (copy number ≥5f o r
samples with ploidy <2.7, and copy number ≥8f o rs a m p l e s
with ploidy ≥2.7) and 436 segments of homozygous
deletions (copy number=0) were identified by ASCAT
[35]. There was marked variation in the number of copy
number changes among samples in the study set, with a
cumulative 5 Gb of losses or gains manifesting in over half
of tumors analyzed. For samples represented by both array
comparative genomic hybridization (aCGH) and ASCAT
data, the frequency recurrence profiles of copy number
changes from ASCAT generally agreed with those from
aCGH performed on the same DNA stock (Additional
file 2: Figure S5).
While the majority of samples (85%) harbored at least
one amplification, only 30% of the samples showed any
homozygous deletions (Additional file 1: Table S5). It is
therefore worth noting that BRAF-driven tumors mutant
in mitf
vc7 had significantly more homozygous deletions
than expected by chance (P =0.01 by Chi-Square test;
Figure 3B). NRAS subtypes, by contrast, did not reveal
apparent commonalities (Figure 3A). Clustering of ASCAT
and aCGH segments from all samples also did not reveal
any regions of subgroup affiliation apart from the strong
amplified signal on chromosomes 18 and 19 (Additional
file 2: Figure S6), the latter of which is believed to be
associated with the BRAF
V600E transgene integration as a
concatemer on chromosome 19.
Identification of a recurrently amplified region in a subset
of zebrafish melanomas
A particularly striking finding was the recurrence of a 175
kb amplicon on chromosome 3 (50.0 to 51.2 Mb) in 10
tumors belonging to the BRAF, p53
-/-, mitf
-/- background
(See figure on previous page.)
Figure 2 Overview of substitutions. (A) The number of substitutions (dark blue columns) and indels (red columns) per sample, corresponding
to their initiating germline mutations (bottom shaded). For p53, light blue indicates p53
+/- and dark blue p53
-/-. Asterisk specifies mitf:MITF
expression in a mitf
-/- background. (B-E) Mutation spectrum of all and selected samples. For all samples (B) mutations are indicated on the
transcribed (T) and untranscribed (UT) strand. (F) Evidence of kataegis within 4,500 bp region in ZD8a, a BRAF;p53 mutant sample. Somatic
mutations are highlighted with colored circles corresponding to the type of substitution.
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http://genomebiology.com/2013/14/10/R113Figure 3 Identification of a frequently amplified locus on chromosome 3. Frequency profiles of tumors mutant in (A) NRAS;p53
-/-;X, (B) BRAF;
mitf
vc7;X tumors and (C) BRAF;p53;mitf
-/-;mitf:MITF;mitf:X, where X can include additional drivers as mentioned in the text. (D) Amplification
segments supporting a peak on chromosome 3 in tumors of BRAF;p53;mitf
-/-;mitf:MITF;mitf:X background derived from exome sequencing
(maroon segments) and aCGH (green dotted segments). Samples mutated are represented by inverted, color-coded triangles above the corre-
sponding gene indicated by the thick black bar. (E) Frequently amplified genes in the entire dataset. (F) Number of copies (y-axis) of the genes
(x-axis) in the region of amplified locus. Each line represents a tumor that is color-coded according to either BRAF;p53;mitf
-/-;mitf:MITF;mitf:X
(yellow) or other (blue) background status. The most frequently amplified genes are highlighted in yellow in (D-F).
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the largest of our dataset (47%, 25/53), the clustering of
the recurrent amplicon in this subgroup was unlikely to
have occurred by chance (P= 0.000256 by Chi-Square
test). Amplified segments were supported by both ASCAT
and aCGH (Figure 3D). The most frequently amplified
genes were prkacaa and samd1 (1 of 2), presenting in
10/53 samples, followed by as1ba (n = 9), wu:fj41e11 (n = 9)
and tecra (n=8) (Figure 3E). While amplifications were
found across all 10 samples for samd1 and prkacaa,t h e y
presented in five or fewer samples for flanking genes
RNF222 and gcgr (Figure 3D).
A simulation was performed to determine the likelihood
of the events occurring in these genes, at this frequency,
by chance. For each sample, the number and lengths of
the amplified segments were randomly introduced across
the target exome regions one million times, producing
a P-value that was adjusted by Bonferroni correction
(n= 6,677). We did not factor causes of amplification
other than those by chance, such as nearby fragile sites,
for which little information is available for zebrafish.
Based on our simulations, all genes recurrently ampli-
fied in six or more samples were likely to be significant,
including prkacaa, samd1, asf1ba, wu:fj41e11 and tecra
(n =13; Additional file 1: Table S6). These genes did not
show evidence of amplification or overexpression in
human cancer datasets (CCLE, Oncomine, COSMIC) or
large, comprehensive melanoma studies [9,10]. Genes
recurrently amplified in fewer samples also showed signifi-
cant enrichment (P≤0.05; Additional file 1: Table S6).
Among these, interestingly, was tert (P=0. 0, n=4 sa m-
ples), which encodes the reverse transcriptase subunit of
telomerase responsible for maintaining the ends of chro-
mosomes. Tert was the only known cancer gene recurrently
mutated in our study set. In human melanoma, TERT is
amplified [10,36] and harbors promoter mutations in as
many as 90% of melanoma cases [7,8].
Identification of few recurrent homozygous deletions
A total of 366 deletion events were identified, affecting
the same genes in at most three samples in the study set
(Figure 4A). By performing the above simulations, we
determined the majority (28/30) of genes deleted in three
samples were unexpected by chance (Additional file 1:
Table S7). The genes nitr1i, nitr3a, nitr7b and nitr7a were
in a locus deleted in three samples belonging to both
BRAF and NRAS mutant lines (Figure 4B). The nitr genes
are members of a highly diversified, multigene family of
novel immune type receptor found in teleosts. Nitr genes
do not rearrange like immune receptors but show struc-
tural similarities to both the mammalian T-cell or Ig-like
r e c e p t o r s[ 3 7 , 3 8 ] .L o s so ft h e s eg e n e sc o u l db er e l e v a n tt o
one facet of progression, which is to avoid immune surveil-
lance, consistent with a critical role of immune regulation
in human melanoma [39]. Other recurrently deleted
genes include sema6d, plcd3a, mrps5, cyp2y3 and xirp
( F i g u r e4 C - H ) ,n o n eo fw h i c hh a db e e np r e v i o u s l yi m -
plicated in human cancer. Further investigation would
provide insights into the contribution of these genes to
tumorigenesis in zebrafish.
Relationships between age, drivers, and mutation burden
We exploited the model system to explore the footprints
of mutagenesis assuming a uniform basal mutational clock.
Where data for the age of fish (at tumor collection)
was available, we found a significant correlation between
age and the number of substitutions using the Pearson’s
correlation test and a generalized linear model (GLM)
(R=0.37, P=0.02, GLM P=0.0035). Positive correlations
have similarly been found in human melanoma [9]. Age of
onset and number of drivers were themselves strongly
negatively correlated. If each germline driver was counted
as one event in a requisite multistep process, we could at-
tempt to delineate a relationship between these initiating
events and extent of the mutations. For transgenic zebra-
fish of the genotype BRAF
V600E;p53
-/-;mitf
-/-;mitf:MITF,a
value of four drivers was assigned, due to the yet unknown
contributions of the additional genes (KROX20, FOXD3,
OCT6) to melanoma. Interestingly, our data showed a
significant, inverse association between the number of
drivers and the substitution events (R=-0.45, P= 0.00075,
GLM P=0.00031), indicating that a greater number of
drivers require fewer additional events to generate the
melanoma lesions. To determine if this correlation
extended to copy number events, we considered each
amplified or deleted segment as an event in the tumor.
Our data showed that if we considered drivers and age
together, this was also a significant predictor of the
total number of copy number events (GLM P= 0.00011;
Additional file 1: Table S8).
Functional categorization of frequently mutated genes
Similar to human cancers, the engineered melanomas
overall displayed high heterogeneity, where the majority
of genes mutated in only one sample (68%; Additional
file 2: Figure S7A). Taking into account all the different
modalities of mutation and their frequencies of occurrence,
a P-value was calculated (using a binomial test) for each
mutated gene (Additional file 1: Table S9). Due to the high
frequency of recurrence, prkacaa and samd1 presented
with the highest significance (P =2 . 3 1×1 0
-8). Following
this, we explored the potential functional themes underlying
these aberrations through a KEGG (Kyoto Encyclopedia of
Genes and Genomes) pathway analysis, which revealed
that the enrichment for most pathways declines when the
minimum threshold for number of mutated samples is
raised (Additional file 2: Figure S7B). From this we infer
that although many genes are not frequently mutated and
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pathways in which they reside are significantly mutated.
Among the enriched pathways in this study (Additional
file 1: Table S10), two include biological processes that
have been directly linked to the hallmarks of cancer
(apoptosis and vascular endothelial growth factor signal-
ing, for angiogenesis), while deregulation of two other
pathways, p53 signaling and melanogenesis (Additional
file 2: Figure S7C), have previously been implicated in
melanoma [40]. Also showing significant enrichment
was the MAPK signaling and cell cycle pathway, thus fur-
ther supporting functions important in human melanoma
development.
Conclusions
We have provided a comprehensive overview of the genetic
events in engineered zebrafish models harboring known
driver alleles. Several new insights into the mutagenic
processes in non-UV-mediated, engineered melanomas,
and the biology of BRAF and NRAS-driven malignancies,
can be drawn from these 53 exomes.
Our results show that in the absence of direct UV
light, engineered melanomas develop similar mutational
signatures to most human cancers, dominated by the
evolutionarily conserved spontaneous deamination of
cytosine to thymidine [9]. We also found rare cases exhi-
biting remarkably distinct mutation spectra, including
A
E
G
F
D C
B
H
Figure 4 Overview of homozygous deletions. (A) Frequency of homozygously deleted genes across samples. (B) Recurrently deleted loci
occurring in at least three samples that are driven by BRAF (dark blue) or NRAS (light blue), and the corresponding genes in these regions (right-
hand side). (C-H) Examples of deleted segments (dark blue bars) and the genes in these regions (labeled at the bottom), represented by their
exon structures (dark blue lines).
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signature.
Importantly, our results demonstrate that tumors driven
primarily by a greater number of known cancer genes
typically manifest with fewer mutations, suggesting that
such models can be used to bound and estimate the
number of events in human cancers. Mouse models of
acute myeloid leukemia and mammary tumors similarly
displayed fewer mutations and structural rearrangements,
respectively, than their human counterparts [41,42]. It
could be speculated that predisposed human individuals
would support the same conclusion. With nearly half
of the samples presenting no substitutions or indels,
however, these two classes of mutations are unlikely to
be the only route to the additional mutations needed
for full melanoma development, with potentially other
factors such as chromatin modifications at play.
The highly recurrent amplicon in transgenic lines with
BRAF;p53;mitf
-/-;mitf:MITF encompassing the genes
prkacaa, samd1, tecra, wu:fj41e11 and asf1b, indicates a
strong selection for genes in this interval in mutant
BRAF, p53 and mitf lines with MITF rescue. Although
the amplicon was exclusive to the BRAF;p53;mitf
-/-;mitf:
MITF transgenic models, it is unclear whether it would
also present in the BRAF or BRAF;p53 mutant models
given a larger sample cohort. Since MITF serves as a
functional rescue in this transgenic line, the genetics of
this subset may be comparable to human tumors that
show dependency on MITF for growth, either through
MITF amplification or overexpression. That none of
the genes in this amplicon have been reported so far as
mutated in human melanoma could therefore be due
to its specific occurrence with BRAF, p53 and amplified
MITF, found in less than 5% of BRAF mutant metastatic
melanomas and a rare combination (Additional file 2:
Figure S8).
In this amplicon, amplification of prkacaa, which encodes
one of two principal catalytic (C) subunits of protein kinase
A( pka), is intriguing for several reasons. Human PRKACA
is the principle catalytic subunit of protein kinase A (PKA)
[43]. Although not previously associated with melanoma,
the cAMP-PKA pathway is a major signal transduction
pathway for melanin production, melanocyte proliferation
and differentiation (reviewed in [44]) and has been impli-
cated in pituitary tumorigenesis [45,46]. Mutations in
PRKAR1A, a PKA-regulatory subunit, cause an inherited
syndrome called the Carney complex, characterized by
pigmented skin lesions, schwannomas, recurrent muco-
cutaneous myxomas and endocrine neoplasms [47,48].
Indeed, cAMP-dependent PKA activation has been shown
to result in the upregulation of the mitf promoter, tyro-
sinase expression and melanin synthesis, affecting skin
pigmentation and melanogenesis [49]. Of interest, re-
cent data have interestingly demonstrated a link between
pigment production and UV-independent melanoma-
genesis, where harmful accumulation of pheomelanin
intermediates or by-products during pigment synthesis
can promote tumor formation [40]. Thus, a potential con-
sequence of PRKACA amplification may be disruption of
PKA signaling and pigment production, pointing to its
possible contribution to aberrant pigment production in
UV-independent carcinogenesis.
An important observation of this study is that, apart from
the amplicon, the BRAF-a n dNRAS-driven melanomas
display striking genetic heterogeneity similar to human
cancers and mouse cancer models [41,42]. One inter-
pretation of this finding is that tumorigenic processes
are achieved through the contribution of many different
mutated genes, in line with previous findings in mice
cooperativity screens [50] and low frequency drivers un-
veiled from emerging studies of human melanoma [9-11].
The enrichment of mutations in pathways known to be
important for melanoma development, such as MAPK
and p53 signaling, in the presence of germline mutations
affecting BRAF, NRAS and p53, also suggest that further
modulation of the signaling of these pathways is required
for full manifestation of the tumors.
To the best of our knowledge, the spectrum of somatic
coding mutations in an engineered model of melanoma
has not yet been described. The integrated analysis we
report here thus provides a glimpse into the genetic paths
to BRAF-a n dNRAS-driven tumorigenesis, providing a
framework for genomic characterization, and a standard
for evaluating and prosecuting detailed biological questions
in engineered animal models of cancer.
Materials and methods
Simulation of zebrafish cancer genomes
Individual zebrafish genomes were created with a SNP
density of 0, 0.001, 0.01, 0.1, and 0.5 SNPs/base by ran-
d o m l yg e n e r a t i n gs u b s t i t u t i o n sa c r o s st h eg e n o m eu s i n ga n
in-house simulation script. Using each individual genome,
referred to as the ‘normal’ , we created a second genome
containing an additional 2,000 substitutions for the ‘tumor’.
For each normal and tumor genome, we simulated 75 bp
reads in FASTQ format using wgsim [51], specifying null
for the base mutation rate, error rate and indel mutation
rate. To simulate normal contamination, we combined
normal and tumor FASTQ files for each individual ac-
cording to the following proportions to obtain an average
sequencing coverage of 80× (Table 2).
The simulated tumor and normal pairs were subse-
quently processed through the Cancer Genome Project
Sequencing Pipeline.
Sample collection
Zebrafish tumor and normal tissue samples were obtained
from Amy Capper and Jennifer Richardson (Elizabeth
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and from Richard White and Charles Kaufman (Len Zon’s
lab, Boston Children’s Hospital, Boston). All samples were
obtained in accordance with the UK Home Office regula-
tions, UK Animals (Scientific Procedures) Act 1986, and
reviewed by the Wellcome Trust Sanger Institute Ethical
Review Committee. Samples from Elizabeth Patton’sl a b
were subject to histopathological review by a clinical
pathologist (Marie Mathers, Edinburgh Western General
Hospital). We were unable to perform histopathology on
samples from Len Zon’s lab. Normal tissue included sec-
tions from the fin, head, or gut. Zebrafish melanoma and
normal DNA were extracted from fresh frozen tissues
using the Qiagen Blood and Tissue DNAeasy Kit (cata-
logue number 69504 (Hilden, Germany)). Melanomas were
derived from transgenic zebrafish expressing either the
BRAF
V600E or NRAS
Q61K human oncogene as previously
described [5,6,18].
Exome bait set
Exon sequences for bait set design were initially down-
loaded from BioMart [52] to encompass all protein coding
genes, and 3’ UTR and 5’ UTR regions from Ensembl
58 of the Zv8 genome. The bait set was subsequently
adjusted to encompass additional genes from Ensembl 61
and new releases of the Zv9 genome (Zebrafish Agilent
All Exon SureSelect). A total of 2,309 Gb of sequencing
was generated, averaging approximately 21.8 Gb per
sample, of which 79.6% of reads mapped and 55% of
which mapped to target coding regions (that is,‘on target’;
Additional file 1: Table S2). By comparison to the human
exome [20], the performance of the zebrafish exome was
slightly lower (in human, 89% of reads map, averaging
62% on target coverage), requiring a greater total
sequencing depth to acquire the desired baseline coverage
of 20×.
DNA and library preparation, capture and sequencing
DNA libraries were prepared using the Illumina Paired
End Sample Prep Kit according to the manufacturer’s
protocol. For targeted enrichment, in the first iteration,
we designed a custom bait set to target the zebrafish
exome for solution capture to include all the exons of all
protein coding genes in the Zv8 Ensembl 58 gene build.
Subsequently, an additional 2,059 genes were added to
include improved annotations in the Zv9 assembly and
Ensembl 59 gene build. Targeted enrichment was per-
formed as described [53] following the manufacturer’s
instructions.
Sequencing with 75 base paired-end reads of targeted-
enrichment libraries was performed on the Illumina GAIIx
and the HiSeq 2000 sequencers. Reads were mapped to the
zebrafish reference (Zv9 Ensembl 61) using the Burrows-
Wheeler algorithm (BWA version 0.5.9) [54] under default
parameters and excluding library PCR duplicates.
Identification of substitution variants
CaVEMan
CaVEMan (cancer variants through expectation maxi-
mization), an in-house algorithm, was employed to call
single nucleotide substitutions in our dataset. Post-
processing filters developed for human variant calling
and additional filters were applied to the set of initial
CaVEMan mutation calls to improve the specificity of
the output.
SomaticSniper
Tumor and normal BAM files were processed by Soma-
ticSniper [21] with a specification for read and base
quality of at least 40. Raw variants were post-processed
using scripts obtained through Github [55], modified to
include a variant allele frequency of no more than 3% in
the normal sample and less than 10% of the tumor, and
without germline SNPs or indels within 5 bp of any of the
normal zebrafish exomes. Variants were annotated using
the Ensembl variant effect predictor (Ensembl 64 gene
build) specifying only coding variants as output.
SGA
SGA analysis was run by Jared Simpson using a modified
algorithm [22].
Identification of insertions and deletions
Insertions and deletions were called using a modified
version of Pindel [23] as previously described [28]. To
improve the identification of high confidence variants,
we specified a requirement for a minimum depth of 15
reads in both tumor and normal samples. For small
Table 2 Metrics for simulating normal contamination in
tumor and normal genome FASTA files
SNP density Type Millions of reads
Normal Tumor content
30% 60% 100%
0 Normal 8 5.6 3.2 0
Tumor 0 2.4 4.8 8
0.001 Normal 8 5.6 3.2 0
Tumor 0 2.4 4.8 8
0.01 Normal 8 5.6 3.2 0
Tumor 0 2.4 4.8 8
0.1 Normal 8 5.6 3.2 0
Tumor 0 2.4 4.8 8
0.5 Normal 8 5.6 3.2 0
Tumor 0 2.4 4.8 8
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by Pindel and at least one by BWA were required. Larger
indels were defined in non-repeat regions where the
mutation was seen once on either strand by Pindel. All
indels were manually reviewed for confirmation.
Variant validation
Capillary and 454 resequencing
Validation of substitutions and indel variants was initially
attempted through capillary or 454 Roche resequencing
of amplified PCR products spanning the mutation in the
tumor and the normal DNA, which had been subject to
whole-genome amplification from the original stock
using GenomiPhi (illustra GenomiPhi HY DNA Amplifi-
cation Kit, catalog number 25-6600-20 (Little Chalfont,
Buckinghamshire, United Kingdom)), according to the
manufacturer’s instructions. Nested PCR improved PCR
yield over a single round of amplification, but both capil-
lary and 454 Roche approaches proved problematic in
PCR-amplified zebrafish DNA.
Targeted capture and Illumina sequencing
To circumvent problems with PCR-based validation, we
designed a custom bait set targeting the mutant alleles for
enrichment followed by Illumina sequencing. We stream-
lined the validation study set by qualitatively reviewing
each variant and keeping only CaVEMAN calls that did
not show germline mutations and were supported by high
quality mapping reads and alignment. An additional 1,700
non-overlapping, Sniper variants (60% of the total non-
overlapping Sniper calls) were selected at random to
include in the validation set, comprising a bait set of 1.4
Mb with minimal tiling probes flanking 60 bp on either
side of each variant. DNA libraries were made as described
above and pooled into eight samples per group with
barcode identifiers. Targeted capture was performed with
each pool according to manufacturer’si n s t r u c t i o n sf o l l o w e d
by 100 bp paired-end sequencing on the Illumina HiSeq
2000 and default BWA alignment. Mutant variants were
confirmed on Samtools Pileup files using a separate, in-
house validation script based on tumor and normal allele
depth and quality. All confirmed variants were subjected to
an additional, manual review.
Identification of copy number variants
Copy number variation was determined primarily through
ASCAT [35]. Only segments under 10 Mb in length were
considered. Genes falling in these segment regions were
annotated using the Ensembl variant effect predictor
(Ensembl 64). Segment data were analyzed using R, Nexus
Copy Number Software 6.1 (Biodiscovery) [56], visualized
using IGV [57,58] and plotted using Progenetix [59].
Array comparative genomic hybridization
aCGH was performed on a subset of 24 zebrafish mel-
anoma normal and tumor samples using a Nimblegen
Custom Design 12×135 K CGH Array (Roche Nimblegen
Technologies, catalogue number 05223881001 (Basel,
Switzerland)) containing 135,000 probes covering the
length of the zebrafish Zv9 genome. In brief, tumor and
normal DNA were labeled, competitively hybridized to the
array for 48 hours, washed and scanned using a 5 micron
scanner (Molecular Devices (Sunnyvale, California, USA)).
Signal intensities were extracted using the DEVA v1.2.1
Software (Nimblegen) [60]. Overall data quality was evalu-
ated as recommended in the DEVA Software User’sG u i d e
[61]. Segmentation was performed using the R Copynum-
ber package [62] and visualized using the Nexus Copy
Number Software (6.1) (Biodiscovery), IGV [57,58] and
Progenetix [59].
Statistical analyses
Codon selection
We used the method described in [63] to evaluate whether
amino acid changes in ZD0038a occurred at a higher
frequency than expected in the absence of positive selec-
tion. Briefly, we used 12 parameters to describe the differ-
ent rates of the 12 possible single nucleotide substitutions,
and two parameters (analogous to dN/dS) to describe se-
lection at missense and nonsense mutations. This allowed
us to quantify the strength of the selection without the
confounding effect of sequence composition and different
rates of each substitution type. Maximum-likelihood
was used to estimate these parameters and likelihood
ratio tests were used to test deviations from neutrality
(dN/dS= 1). Analogous results to those presented in
the main text were obtained using the traditional
codon model approach used in phylogenetic analyses
(implemented in [64]) as well as accounting for CpG
context-dependent effects.
Estimation of the number of mutated copies
Allele-specific copy number estimates for point mutations
were obtained by integrating copy number and sequencing
data as described in [35].
Simulations of amplifications and homozygous deletions
Genes showing enrichment of amplifications were identi-
fied by permutation analysis, where 1,000,000 permutations
were performed randomizing the positions (but not the
size) of amplifications, for each sample. For each permuta-
tion and each gene, the number of samples that were hit
by an amplification was counted and the probability that
each gene was significantly enriched for amplifications
was calculated as the proportion of the permutations in
which that gene had as many, or more, amplifications
than were observed in the ‘real’ data. Probabilities were
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tion (n=6,677, the number of genes tested).
Evaluation of driver and age correlation
Mutation burden and driver correlation was performed
as previously described [20].
Pathway analysis
Mutation significance analysis
We combined mutation data from substitutions, insertions
and deletions, and copy number changes (amplifications
and homozygous deletions) to assess the likelihood of a
gene being mutated in more samples than expected by
chance. As each mutation type can occur at a different
frequency (where amplifications are more frequent than
deletions), each mutation type was considered separately.
Thus, to calculate a combined P-value for each gene j,w e
used the following Equation 1:
pj ¼ ∏
i∈ 1;2;3;4 fg
P
 
X≥xijjqi;ni
 
¼ ∏
i∈ 1;2;3;4 fg
1−
X k¼xij−1
k¼0
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qi ðÞ
k 1−qi ðÞ
ni−k
 !
;
ð1Þ
where xij is the number of samples carrying a mutation in
gene j in sample group i and ni the number of samples in
sample group i.M o r e o v e r ,qi was calculated as follows:
qi−
1
ni
X ni
k¼1
1− 1−
1
N
   mk
;
with N number of genes in the genome.
Entrez gene mapping
For compatibility with the KEGG database, we mapped
Danio rerio Ensembl IDs onto Entrez IDs using NCBI
[65], which includes a cross-reference of Entrez to
Ensembl. Target genes that could not be matched in this
fashion were matched using gene symbol and synonyms.
Pathway analysis
We used knowledge from the KEGG database to construct
a large protein interaction network. To gauge whether a
pathway contains more frequently mutated genes than
expected by chance, a KEGG pathway enrichment was
performed for all 215 pathways in the Danio rerio specific
KEGG database.
All genes with a combined P-value <0.05 (as calculated
according to the mutation significance analysis) were
selected for the pathway analysis. This cutoff selected
for genes with at least two amplifications, and given rarer
mutation types, genes with at least one mutation other
than an amplification.
We called a gene frequently mutated if it carried at
least N mutations, where N can be between 1 and 10
(Additional file 1: Table S9). Genes with mutation counts
of three or more were visualized in the context of their
KEGG pathway interactions using Cytoscape [66].
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